FHD-286 is an oral inhibitor of the BAF complex for treating AML and uveal melanoma (UM).FHD-286 inhibits BAF function by inhibiting the ATPase components of the BAF complex, SMARCA4, and SMARCA2 (133, 134). This evidence concerns the gene BANF1 and acute myeloid leukemia.